Pursuant to Regulation 30 of the Listing Regulations, Lal PathLabs has informed that it enclosed the Press Release titled ‘Dr. Lal PathLabs Strengthens Autoimmune Diagnosis with India’s First Comprehensive Complement Lab’.
The above information is a part of company’s filings submitted to BSE.